RATIONALE: We previously colocalized a quantitative trait locus (QTL) for sensitivity to the locomotor stimulant effects of methamphetamine (MA) with a QTL for expression of casein kinase 1 epsilon (Csnk1-epsilon) in the nucleus accumbens (NAc). Subsequently, we identified a single nucleotide polymorphism in CSNK1E (rs135745) that was associated with increased sensitivity to the subjective effects of d-amphetamine in healthy human subjects. Based on these results, we hypothesized that differential expression of Csnk1-epsilon causes differential sensitivity to MA-induced locomotor activity in mice. OBJECTIVE: In the present study, we used PF-670462 (PF), which is a selective inhibitor of Csnk1-epsilon, to directly evaluate the role of Csnk1-epsilon in the locomotor stimulant response to MA in male C57BL/6J mice. METHODS: We administered vehicle, PF, MA, or MA + PF, either via intraperitoneal injections or bilateral intra-NAc microinjections. We also examined Darpp-32 phosphorylation in mice receiving intraperitoneal injections. RESULTS: Intraperitoneal PF (20-40 mg/kg) attenuated the locomotor stimulant response to MA (2 mg/kg) without affecting baseline activity. The high dose of PF also significantly inhibited MA-induced phosphorylation of Darpp-32, providing a potential mechanism by which Csnk1-epsilon contributes to MA-induced locomotor activity. Furthermore, microinjection of PF (5 microg/side) into the NAc completely blocked the locomotor stimulant response to MA (2.5 microg/side) without affecting baseline activity. CONCLUSIONS: These results provide direct evidence that Csnk1-epsilon is crucial for the locomotor stimulant response to a moderate dose of MA and suggest that genetic polymorphisms affecting Csnk1-epsilon expression or function could influence sensitivity to amphetamines in both mice and humans.
RATIONALE: We previously colocalized a quantitative trait locus (QTL) for sensitivity to the locomotor stimulant effects of methamphetamine (MA) with a QTL for expression of casein kinase 1 epsilon (Csnk1-epsilon) in the nucleus accumbens (NAc). Subsequently, we identified a single nucleotide polymorphism in CSNK1E (rs135745) that was associated with increased sensitivity to the subjective effects of d-amphetamine in healthy human subjects. Based on these results, we hypothesized that differential expression of Csnk1-epsilon causes differential sensitivity to MA-induced locomotor activity in mice. OBJECTIVE: In the present study, we used PF-670462 (PF), which is a selective inhibitor of Csnk1-epsilon, to directly evaluate the role of Csnk1-epsilon in the locomotor stimulant response to MA in male C57BL/6J mice. METHODS: We administered vehicle, PF, MA, or MA + PF, either via intraperitoneal injections or bilateral intra-NAc microinjections. We also examined Darpp-32 phosphorylation in mice receiving intraperitoneal injections. RESULTS: Intraperitoneal PF (20-40 mg/kg) attenuated the locomotor stimulant response to MA (2 mg/kg) without affecting baseline activity. The high dose of PF also significantly inhibited MA-induced phosphorylation of Darpp-32, providing a potential mechanism by which Csnk1-epsilon contributes to MA-induced locomotor activity. Furthermore, microinjection of PF (5 microg/side) into the NAc completely blocked the locomotor stimulant response to MA (2.5 microg/side) without affecting baseline activity. CONCLUSIONS: These results provide direct evidence that Csnk1-epsilon is crucial for the locomotor stimulant response to a moderate dose of MA and suggest that genetic polymorphisms affecting Csnk1-epsilon expression or function could influence sensitivity to amphetamines in both mice and humans.
Authors: Venetia Zachariou; Véronique Sgambato-Faure; Teresa Sasaki; Per Svenningsson; Olivier Berton; Allen A Fienberg; Angus C Nairn; Paul Greengard; Eric J Nestler Journal: Neuropsychopharmacology Date: 2006-03 Impact factor: 7.853
Authors: Jeremy Veenstra-VanderWeele; Asfia Qaadir; Abraham A Palmer; Edwin H Cook; Harriet de Wit Journal: Neuropsychopharmacology Date: 2006-05 Impact factor: 7.853
Authors: Abraham A Palmer; Miguel Verbitsky; Rathi Suresh; Helen M Kamens; Cheryl L Reed; Na Li; Sue Burkhart-Kasch; Carrie S McKinnon; John K Belknap; T Conrad Gilliam; Tamara J Phillips Journal: Mamm Genome Date: 2005-05 Impact factor: 2.957
Authors: Colleen A McClung; Kyriaki Sidiropoulou; Martha Vitaterna; Joseph S Takahashi; Francis J White; Donald C Cooper; Eric J Nestler Journal: Proc Natl Acad Sci U S A Date: 2005-06-20 Impact factor: 11.205
Authors: Axel C R Diernfellner; Christina Querfurth; Carlos Salazar; Thomas Höfer; Michael Brunner Journal: Genes Dev Date: 2009-09-15 Impact factor: 11.361
Authors: Laura J Sittig; Choongwon Jeong; Emily Tixier; Joe Davis; Camila M Barrios-Camacho; Abraham A Palmer Journal: Mamm Genome Date: 2014-07-05 Impact factor: 2.957
Authors: Riyan Cheng; Jackie E Lim; Kaitlin E Samocha; Greta Sokoloff; Mark Abney; Andrew D Skol; Abraham A Palmer Journal: Genetics Date: 2010-05-03 Impact factor: 4.562
Authors: Dongdong Li; Stacy Herrera; Nancy Bubula; Elena Nikitina; Abraham A Palmer; Dorothy A Hanck; Jessica A Loweth; Paul Vezina Journal: J Neurochem Date: 2011-06-06 Impact factor: 5.372